A Phase II Trial of AZD0530 in Hormone Refractory Prostate Cancer (HRPC).
Phase of Trial: Phase II
Latest Information Update: 21 Apr 2018
At a glance
- Drugs Saracatinib (Primary)
- Indications Prostate cancer
- Focus Biomarker; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 13 Nov 2008 Status changed from active, no longer recruiting to completed, as reported in ClinicalTrials.gov record.
- 25 Mar 2008 Status changed from recruiting to in progress, as reported by ClinicalTrials.gov.